adobe stock photos - JHVEPhotoAutoimmune diseasesSanofi receives US approval for oral ITP blockbusterSanofi SA has received FDA marketing approval for Wayrilz (rilzabrutinib). Unlike three existing causal treatments for immune thrombocytopenia (ITP), the oral drug inhibits both processes that drive … more ➔
ForbionLicence dealSitalaBio pays US$670m for Fosun inflammation blockerBritish company Sitala Bio Ltd, founded in 2021 by NLRP3 inflammasome expert Matt Cooper, is paying US$670m and giving up to 10% of its shares to Chinese company Shanghai Fosun Pharmaceutical Group Co. … more ➔
Adobe stock photos - JimObesityLilly’s weight loss pill orforglipron meets primary Phase III endpointEli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met … more ➔
Calluna Pharma A/SClinical trialsCalluna Pharma starts efficacy test with unique IPF antibodyNorway-based Calluna Pharma A/S has initiated patient recruitment in late August for its Phase II AURORA trial investigating safety and efficacy of CAL101, a monoclonal antibody with unique mode of action … more ➔
BioArctic ABNeurodegenerationNovartis secures US$30m+ licence option from BioArcticFollowing the commercial launch of BioArctic AB’s Alzheimer’s antibody lecanemab, the Swedish company has announced a new deal: it will receive an upfront payment of US$30m, granting the Swiss company … more ➔
Esai PharmaDementiaAlzheimer’s antibody Lecanemab launched in the EUSwedish BioArctic AB’s partner Eisai Pharma has started the European roll-out of their Alzheimer’s antibody lecanemab in Austria that will be followed by the German launch on September 1, 2025. more ➔
EFPIAUS-EU trade conflictUS and EU confirm tariff deal on pharmaceuticals, generics largely exemptThe US and EU have confirmed a trade agreement involving US import tariffs of 15% on prescription medicines. Generics manufacturers will face a maximum tariff of 2.5%. more ➔
MalliaHair growthMallia Aesthetics is about to launch MAL-838Germany’s Mallia Aesthetics GmbH has announced the achievement of key regulatory milestones in preparation for the market launch of its sCD83-based hair growth stimulant, MAL-838, later this year. … more ➔
BioMed XMetabolic DisordersBioMed X and Novo Nordisk collaborate to optimise oral peptide therapeuticsNovo Nordisk has entered a collaboration with research institute BioMed X in an effort to regain market position lost to leading competitors in diabetes and obesity treatment. The partnership is focused … more ➔
Anocca ABImmunoncologyAnocca raises €38.4m to advance TCR-T leads vs. pancreatic cancerSwedish immunoncology specialist Anocca AB has raised SEK440m (€38.36m) ahead of enrolling pancreatic cancer patients in a Phase I umbrella trial evaluating the safety of its T-cell receptor-engineered … more ➔
adobe stock photos - JHVEPhoto
Forbion
Adobe stock photos - Jim
Calluna Pharma A/S
BioArctic AB
Esai Pharma
EFPIA
Mallia
BioMed X
Anocca AB